{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:44:09Z","timestamp":1777254249069,"version":"3.51.4"},"update-to":[{"DOI":"10.12688\/f1000research.122945.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000}}],"reference-count":33,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"None"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    <ns3:bold>Background:<\/ns3:bold>\n                    Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple randomized clinical trials have demonstrated its efficacy in psoriasis, but response differences among patient subpopulations have not been extensively reported. Furthermore, patients in real life are often non-eligible for clinical trials and their responses may differ from pivotal studies.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Methods<\/ns3:bold>\n                    : This is a retrospective, observational study of real clinical practice of patients receiving guselkumab treatment in Spain. Patients treated with guselkumab were included between February 2019 to December 2021. This study evaluates the potential differential effect of baseline demographic and disease characteristics on therapeutic responses to guselkumab. We measured effectiveness and survival by the psoriasis area and severity index, the dermatology life quality index as well as Kaplan meier curves, respectively. Categorical and quantitative variables are reported with frequencies, and with mean and standard deviation, respectively. Differences between groups in psoriasis area and severity index and dermatology life quality index, were calculated using a mixed-effects analysis. Survival was calculated using Kaplan meier curves and log-rank tests.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Results<\/ns3:bold>\n                    : A total of 87 patients were included. In this study, our objective was to evaluate the effectiveness, safety and survival of guselkumab attending to demographic characteristics. No differences in psoriasis area and severity index or dermatology life quality index baseline values or therapeutic responses were noted at 52 weeks of follow-up among all the subgroups analysed (age, sex, psoriasis duration, body mass index, and comorbidities). A difference in drug survival was only seen between gender groups.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Conclusions:<\/ns3:bold>\n                    Our research has demonstrated the consistency of guselkumab effectiveness across patient subgroups. No baseline features affected the effectiveness or drug survival of guselkumab, except for lower drug survival in female patients.\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.122945.2","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:35:06Z","timestamp":1667824506000},"page":"1178","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study"],"prefix":"10.12688","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Rodriguez-Fernandez-Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C.","family":"Armario-Hita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"P\u00e9rez-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Vasquez Chinchay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gal\u00e1n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1029-1033","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.","volume":"61","author":"R Ruiz-Villaverde","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00116-9","article-title":"Quality of life of patients living with psoriasis: a qualitative study.","author":"S Meneguin","year":"cited 2022 May 31"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"326-338","DOI":"10.1056\/nejmoa1314258","article-title":"Secukinumab in Plaque Psoriasis \u2014 Results of Two Phase 3 Trials.","volume":"371","author":"R Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"345-356","DOI":"10.1056\/nejmoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.","volume":"375","author":"K Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"405-417","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial.","volume":"76","author":"A Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"650-661","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"K Gordon","year":"2018","journal-title":"Lancet."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1064-1067","DOI":"10.1038\/JID.2008.85","article-title":"T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis.","volume":"128","author":"A Blauvelt","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"114-123","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.","volume":"178","author":"R Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14798","article-title":"Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.","volume":"34","author":"R Ruiz-Villaverde","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"57-71","DOI":"10.1016\/J.DET.2014.09.005","article-title":"Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice.","volume":"33","author":"R Chalmers","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref11","article-title":"Dermatology Life Quality Index (DLQI)-a Simple Practical Measure for Routine Clinical Use.","volume":"19","author":"A Finlay","year":"1994"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"132-139","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies Funding sources.","volume":"178","author":"K Gordon","year":"2018","journal-title":"British Journal of Dermatology Linked Comment: Feldman Br. J. Dermatol."},{"key":"ref13","article-title":"Global report on psoriasis.","year":"2016 cited 2022 May 31"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"831-839","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"K Reich","year":"2019 Sep 7","journal-title":"Lancet."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"173-194","DOI":"10.1007\/s13555-018-0230-9","article-title":"Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.","volume":"8","author":"J Carrascosa","year":"2018 Jun","journal-title":"Dermatol. Ther. (Heidelb)."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"355-371","DOI":"10.2217\/imt-2020-0040","article-title":"Guselkumab in the treatment of moderate-to-severe plaque psoriasis.","volume":"12","author":"C L\u00f3pez-S\u00e1nchez","year":"2020 Apr","journal-title":"Immunotherapy."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1945-1960","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.","volume":"323","author":"A Armstrong","year":"2020 May 19","journal-title":"JAMA."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"83-97","DOI":"10.2147\/PTT.S294173","article-title":"Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics.","volume":"11","author":"H Ben Abdallah","year":"2021","journal-title":"Psoriasis (Auckl)."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5-13","DOI":"10.1080\/1744666X.2020.1857733","article-title":"Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.","volume":"17","author":"W Boehncke","year":"2021 Jan","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"418-431","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"K Reich","year":"2017 Mar","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref22","first-page":"826-832","article-title":"Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.","volume":"17","author":"C Griffiths","year":"2018 Aug 1","journal-title":"J. Drugs Dermatol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"848-856","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.","volume":"33","author":"C Griffiths","year":"2020 Jul 13","journal-title":"J. Dermatolog. Treat."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"936-945","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.","volume":"82","author":"K Reich","year":"2020 Apr","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e837-e839","DOI":"10.1111\/jdv.16715","article-title":"Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study.","volume":"34","author":"F Benhadou","year":"2020 Dec","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e644-e646","DOI":"10.1111\/jdv.16511","article-title":"Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study.","volume":"34","author":"A Fougerousse","year":"2020 Oct","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"342-343","DOI":"10.1080\/09546634.2019.1605133","article-title":"Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review.","volume":"31","author":"E Lee","year":"2020 Jun","journal-title":"J. Dermatolog. Treat."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1074-1078","DOI":"10.1080\/09546634.2020.1800577","article-title":"Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.","volume":"33","author":"M Megna","year":"2020 Aug 4","journal-title":"J. Dermatolog. Treat."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e14584","DOI":"10.1111\/dth.14584","article-title":"Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.","volume":"34","author":"C Bonifati","year":"2021 Jan","journal-title":"Dermatol. Ther."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"588-595","DOI":"10.1177\/1203475420932514","article-title":"Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab.","volume":"24","author":"K Maliyar","year":"2020 Dec","journal-title":"J. Cutan. Med. Surg."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14673","article-title":"Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti- interleukin -17 treatment: A real-life 52-week retrospective study.","volume":"34","author":"A Ruggiero","year":"2020 Dec","journal-title":"Dermatol. Ther."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072170","article-title":"Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study.","volume":"9","author":"M Galluzzo","year":"2020 Jul 9","journal-title":"J. Clin. Med."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e13964","DOI":"10.1111\/dth.13964","article-title":"Real-life experience of guselkumab in patients with psoriasis.","volume":"33","author":"I Snast","year":"2020 Nov","journal-title":"Dermatol. Ther."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.20981053.v1","article-title":"Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study. figshare. Dataset.","author":"R Ruiz-Villaverde","year":"2022"}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T10:15:31Z","timestamp":1671099331000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":33,"URL":"https:\/\/doi.org\/10.12688\/f1000research.122945.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.140623.r154409","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.140623.r155169","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.140623.r154409","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.140623.r155169","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.140623.r155169, Pedro Mendes Bastos, Dermatology Center, Hospital CUF Descobertas, Lisboa, Portugal, 16 Nov 2022, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2#referee-response-155169","order":0,"name":"referee-response-155169","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.140623.r154409, Jose Manuel Carrascosa, Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 15 Dec 2022, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1178\/v2#referee-response-154409","order":1,"name":"referee-response-154409","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}